期刊文献+

川芎嗪对阿霉素肾病肾小管间质损伤影响的实验研究

Experimental study regarding to the effects of ligustrazine on renal tubulointerstitial injury in adria- mycin nephrosis rats
原文传递
导出
摘要 目的 观察川芎嗪对阿霉素肾病肾小管间质损伤的影响,并探讨其可能的机制.方法 雄性SD大鼠40只,按简单随机法分为假手术组、模型组、川芎嗪组及苯那普利组,采用左侧肾脏切除加尾静脉重复注射阿霉素的方法建立阿霉素肾病模型.检测各组大鼠在阿霉素注射前(0周末),用药2周末、4周末、6周末24h尿蛋白量;观察用药6周末各组大鼠肾功能指标及光镜下肾脏的病理改变,应用免疫组化方法测定肾小管间质内皮素-1(Endothelin-1 ET-1)的表达.结果 模型组24h尿蛋白量[(30.07±2.12) mg/24 h、(201.83 ±8.63) mg/24 h、(470.70 ±58.79) mg/24 h](用药2周末、4周末、6周末)、血尿素氮[ (20.20 ±2.65) mmol/L]、肌酐[(86.79 ±2.20) μmol/L]水平、肾小管间质的损伤PAS评分(4.38 ±0.26)及ET-1表达(126.92 ±3.63)均显著高于假手术组[分别为(6.75±2.07) mg/24 h、(8.28±0.71 )mg/24 h、(25.37±4.30) mg/24 h、(8.93±1.05) mmol/L、(49.00±5.34) μmol/L、1.06±0.19、32.09±3.71;P<0.01];川芎嗪组24h尿蛋白量[(176.93±9.20)mg/24 h、(270.45 ±60.21)mg/24 h](4周末、6周末)、血尿素氮[(13.75 ±2.60) mmol/L]、肌酐[ (62.49 ±3.29)μmol/L]水平、肾间质小管的损伤PAS评分(2.78±0.10)及ET-1表达(57.44±4.98)均显著低于模型组(P<0.01).结论 川芎嗪对肾间质小管损伤有保护作用,其机制与减少尿蛋白的排泄,抑制ET-1的生成有关,从而减轻肾小管间质的炎症反应及纤维化. Objective To investigate the effects of ligustrazine on renal tubulointerstitial injury in adriamycin nephrosis rats and its mechanism.Methods Forty male Sprague-Dawley rats were randomly divided into sham-operation group,model group,ligustrazine group and Benazepril group.The rat nephropathy model was established by adriamycin injection and unilateral nephrectomy.The 24-hour urinary protein excretion at the start,2nd,4th,6th weekends was analyzed.All rats were sacrificed at the 6th weekend,and then the renal function and the tubulointerstitial pathological injury were examined.Immunohistochemistry was used to measure the expression of ET-1.Results The 24-hour urinary protein excretion [ (30.07 ±2.12) mg/24 h,(201.83 ± 8.63 ) mg/24 h,( 470.70 ± 58.79 ) mg/24 h ] ( at the 2th,4th,6th weekend),blood urea nitrogen[ BUN( 20.20 ± 2.65 ) mmol/L],serum creatinine[ Scr ( 86.79 ± 2.20 ) μmol/L),tubulointerstitial pathological injury (4.38 ± 0.26) and the expression of ET-1 ( 126.92 ± 3.63 )in model group were significantly higher than those in sham-operation group [ ( 6.75 ± 2.07 ) mg/24 h,( 8.28 ± 0.71 ) mg/24h,( 25.37 ± 4.30) mg/24 h,( 8.93 ± 1.05 ) mmol/L,(49.00 ± 5.34 ) μmol/L,1.06 ± 0.19,32.09 ± 3.71,P 〈 0.01 ].Compared with model group,the 24-hour urinary protein excretion [ ( 176.93 ± 9.20)mg/24 h,( 270.45 ± 60.21 ) mg/24 h) ( at the 4th,6th weekend),BUN [ ( 13.75 ± 2.60 ) mmol/L ],Scr [ ( 62.49 ±3.29)μmol/ L ],Renal tubulointerstitial pathological injury (2.78 ± 0.10) and the expression of ET-1(57.44 ± 4.98 ) were significantly decreased in ligustrazine group( P 〈 0.01 ).Conclusions Ligustrazine can downregulate the expression of ET-1 and decreased urinary protein excretion,leading to reduce tubulointerstitial inflammation and fibrosis.
出处 《中国医师杂志》 CAS 2011年第12期1599-1602,共4页 Journal of Chinese Physician
基金 基金项目:湖南省卫生厅基金(B2008-060)
关键词 川芎嗪/药理学 肾病/中药疗法/病理学 表柔比星/副作用 肾小管/病理学/药物作用 TETRAMETHYLPYRAZINE/PD Nephrosis/ZD/PA Epirubicin/AE Kidney tubules/PA/DE
  • 相关文献

参考文献8

  • 1杨俊伟.肾小管问质疾病的动物模型//王海燕.肾脏病学.3版北京:人民卫生出版社,2008:619-629.
  • 2Sue YM, Cheng CF, Chang CC, et al. Antioxidation and anti-intlammalion by haem oxygenase-1 contribute to protection by tetramethylpyrazine against gentamicin-induced apoptosis in routine renal tubular cells. Nephrol Dial Transplanl,2009,24(3) :769-777.
  • 3张丽芬,黄文政,朱小棣,王耀光.阿霉素肾病肾小球硬化动物模型的研究[J].中国中西医结合肾病杂志,2005,6(4):195-199. 被引量:55
  • 4李宏,李荣山,乔晞,朱国贞,黄晓光,邵珊,白波.intermedin对大鼠肾脏缺血再灌注损伤的保护作用及其机制[J].中华肾脏病杂志,2010,26(8):614-618. 被引量:13
  • 5甘泉,方建新.伊贝沙坦治疗老年早期糖尿病肾病的临床观察[J].医学临床研究,2008,25(2):306-307. 被引量:1
  • 6Ruggenenti P, Remuzzi A, Remuzzi G, et al. The Remission Clinic approach to halt the progression of kidney disease. J Nephrol, 2011,24(3):274-281. doi: 10.5301/JN.2011.7763.
  • 7Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol,2006,17 (4) :943-955.
  • 8Richter CM. Role of endothelin in chronic renal failure-developments in renal involvement. Rheumatology( Oxford ), 2006,45 Suppl 3 : iii36-iii38.

二级参考文献27

  • 1赵军宁,谭永淑,姚先莹.阿霉素肾病模型研究进展[J].四川生理科学杂志,1995,17(1):34-39. 被引量:10
  • 2孙世澜,曾红兵.老年人糖尿病肾病的治疗[J].中华老年医学杂志,2006,25(1):18-19. 被引量:25
  • 3Nishimatsu H,Hirata Y,Shindo T,et al.Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury:studies on transgenic/knockout mice of adrenomedullin gene.Circ Res,2002,90:657-663.
  • 4Yang JH,Qi YF,Jia YX,et al.Protective effects of intermedin/adrenomedullin 2 on ischemia/repeffusion injury in isolated rat hearts.Peptides,2005,26:501-507.
  • 5Yang JH,Jia YX,Pan CS,et al.Effects of intermedin(1-53)on cardiac function and ischemia/reperfusion injury in isolated rat hearts.Biochem Biophys Res Commun,2005,327:713-719.
  • 6Bengatta S,Arnould C,Letavemier E,et al.MMP9 and SCF protect from apoptosis in acute kidney injury.J Am Soc Nephrol,2009,20:787-797.
  • 7Roh J,Chang CL,Bhalla A,et al.Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes.J Bioi Chem,2004,279:7264-7274.
  • 8Takei Y,Inoue K,Ogoshi M,et al.Identification of novel adrenomedullin in mammals:a potent cardiovascular and renal regulator.FEBS Lett,2004,556:53-58.
  • 9Fujisawa Y,Nagai Y,Miyatake A,et al.Renal effects of a new member of adrenomodullin family,adrenomedullin2,in rats.Eur J Pharmacol,2004,497:75-80.
  • 10Bell D,McDermott BJ.Intermedin(adrenomedullin-2):a novel counter-regulatory peptide in the cardiovascular and renal systems.Br J Pharmacology,2008,153:247-262.

共引文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部